Study: Chocolate chip cookies as addictive as cocaine

chocolate chip cookies_1536090725178.jpg.jpgStudy: Chocolate chip cookies as addictive as cocaine

https://www.wowktv.com/news/u-s-world/study-chocolate-chip-cookies-as-addictive-as-cocaine/

BORDEAUX, France (WIAT) — Having a hard time staying away from the cookie jar? According to the smart cookies behind a recent study, there’s a reason you can’t deny your sugar cravings.

Researchers at the University of Bordeaux say the combination of ingredients in a traditional chocolate chip cookie trigger the same addictive response in your brain as cocaine or marijuana.

“Overall, this research has revealed that sugar and sweet reward can not only substitute to addictive drugs, like cocaine but can even be more rewarding and attractive,” the study’s abstract posits.

Like your cookies with a dash of salt? Your brain does too. Salt consumption activates the brain’s reward centers, compounding the already addictive effects of these chocolaty treats.

So the next time your cookie cravings compel you to act against your better judgment, don’t beat yourself up about it. It’s basically a natural human response, the study shows.

Chocolate chip cookies account for about a fifth of the global cookie market, which is expected to become a $38 billion industry by 2022.

Last-ditch opioid settlement in Ohio could open door for much larger deal

Last-ditch opioid settlement in Ohio could open door for much larger deal

https://www.washingtonpost.com/health/ohio-counties-drug-firms-reach-260m-settlement-averting-trial/2019/10/21/c9ac1dd4-f39f-11e9-ad8b-85e2aa00b5ce_story.html

CLEVELAND — Two Ohio counties and four drug companies settled a landmark lawsuit over responsibility for the opioid epidemic Monday in a deal that could help push the parties toward a wide-ranging agreement on more than 2,400 similar claims filed across the country.

The $260 million settlement, reached just hours before opening arguments were scheduled to begin in the first federal lawsuit of the opioid era, will give Cuyahoga and Summit counties badly needed cash and anti-addiction medication. Those will be provided by mammoth opioid distributors McKesson Corp., AmerisourceBergen and Cardinal Health, and drug manufacturer Teva Pharmaceuticals, four of the defendants in the first case.

But the agreement also may help guide the next round of negotiating as drug companies and governments that have sued them continue efforts to resolve the remaining legal actions all at once. “Hopefully it’s a first step. We learned a lot. I think the defendants learned a lot” as the case moved toward trial, said Joseph F. Rice, one of the lead attorneys for the cities and counties whose cases have been consolidated into one “multidistrict litigation” in the federal courthouse here.

“And I believe there are a lot of corporations involved in the opioid crisis . . . that recognize that it’s time for them to contact us, and let’s see if we can put everybody together and get a global settlement.”

Two Ohio counties settled on Oct. 21 with four drug companies before the start of a landmark federal trial over who is responsible for the opioid epidemic. (Luis Velarde/The Washington Post)

The Ohio deal ratchets up the pressure on plaintiffs and drug companies to reach a global settlement or, some argue, to cut their own deals sooner. If the hundreds of lawsuits filed by cities, counties, Native American tribes and others continue to be settled individually, the first jurisdictions are likely to get larger payouts, attorneys said.

“This is a national crisis that demands a national solution,” said North Carolina Attorney General Josh Stein said on a conference call Monday afternoon. “The trial date has now been resolved. It’s in the past. And we can focus on coming up with what is going to do the best for our people.”

But finding such a solution is posing challenges amid the tensions between the mostly private lawyers representing local governments and the elected state attorneys general, as well as between states devastated by the opioid crisis and those less affected.

‘Why can’t I have the medicine I need?’: A painful new reality for patients who rely on opioids
Hank Skinner uses a fentanyl patch to treat his chronic pain. Now his doctor is lowering the dose – a new reality for millions relying on high doses of opioids. (Video: Dalton Bennett/Photo: Salwan Georges/The Washington Post)

In a moment of high drama Monday, U.S. District Judge Dan Aaron Polster, who has pushed for that global settlement for nearly two years, took his seat at the bench at 9:01 a.m. and announced the two-county Ohio settlement, which had leaked to the media before he spoke.

“I hope very productive discussions continue and we don’t lose the momentum that was created,” Polster said.

Hours later, a bipartisan group of state attorneys general said they had reached a $48 billion agreement in principle with the same four companies and Johnson & Johnson for a much larger nationwide deal.

They said they would press cities and counties to back the global settlement — $22 billion in cash paid out over 18 years, and $26 billion in anti-addiction and drug treatment medication.

But that proposal is nearly the same one lawyers for the cities and counties rejected after 10 hours of bargaining Friday, and the lawyers were quick to say Monday that the sum is too small and the payout period much too long.

“They can keep repeating the same offer, but that doesn’t mean it’s going to happen, because it’s not,” said Paul J. Hanly Jr., another attorney for the cities and towns. “A majority of the towns and cities are opposed to this, and they are not going to accept it.”

Democrats Stein of North Carolina and Josh Shapiro of Pennsylvania have been leading the negotiations for a proposed $48 billion national settlement, along with Republican attorneys general Herbert H. Slatery III of Tennessee and Ken Paxton of Texas.

In a conference call with reporters Monday, the four acknowledged the difficulty of persuading the cities and counties — as well as other attorneys general — to go along.

Asked on the call how many of their state counterparts were on board, the attorneys general declined to provide a number.

One proposal under discussion is to create a large national trust fund with rules under which cities, counties, states and others could apply for the money, said an attorney who spoke on the condition of anonymity because the idea is in its early stages. Polster or his designee might be tapped to control the fund, said the attorney.

More than 200,000 people have died of overdoses of prescription narcotics in the past two decades, and another 200,000 have succumbed to overdoses of heroin and illegal fentanyl, which is now the main driver of the worst drug crisis in U.S. history.

In August, an Oklahoma judge found health care giant Johnson & Johnson liable for fueling the opioid epidemic in the first state court trial of its kind and ordered the company to pay $572 million. Johnson & Johnson has appealed that decision.

Polster selected the two Ohio counties in Monday’s trial as a “bellwether” case, one designed to determine, via a jury verdict, how other plaintiffs might fare. A trial could have cost the companies more than $8 billion if the counties were awarded all the money they were seeking.

In settling the case, however, the companies admitted no wrongdoing.

Greg McNeil, whose son became addicted to pain pills and died of a heroin overdose in 2015, said outside Polster’s 18th-floor courtroom that families would have liked an apology from the companies.

“A settlement with an admission of wrongdoing would have begun to bring closure for families who have lost loved ones to the opioid epidemic,” he said. “Sadly, that didn’t happen.”

Plaintiffs’ attorneys said this and previous settlements were tantamount to an admission of culpability. “They paid over $323 million to these two counties,” when previous settlements by Johnson & Johnson, Mallinckrodt Pharmaceuticals and other drug companies are included, Rice said. “One might say that’s a pretty good admission.”

Ilene Shapiro, county executive for Summit County, said the counties had sent a message to the drug industry.

“We started this originally to stop the [drug companies’] behaviors — to hold these folks accountable,” she said. “Enough is enough. We’ve got people dying on our streets.”

The three wholesale distributors released a joint statement saying that “while the companies strongly dispute the allegations made by the two counties, they believe settling the bellwether trial is an important steppingstone to achieving a global resolution and delivering meaningful relief.

“The companies expect settlement funds to be used in support of initiatives to combat the opioid epidemic, including treatment, rehabilitation, mental health and other important efforts.”

Walgreens, a fifth defendant, did not take part in the settlement. Its trial was postponed until early next year, when it may be joined by other companies that were dropped from the first trial by mutual consent.

The company issued a statement saying that the allegations against it were very different from those against the others companies. “We never manufactured, marketed or wholesaled prescription opioid medications,” the statement said. “Our pharmacists have always been committed to serving patients in the communities where they live and work.”

A sixth defendant, Henry Schein Medical, which distributed a tiny amount of opioids in Summit County and was sued only by that jurisdiction, said it had also reached a deal. Under the plan, the company will donate $1 million to establish an educational foundation in Summit County that will develop best practices for the proper use of prescription opioids and will pay $250,000 of Summit County’s legal expenses.

The two-county Ohio settlement follows the collapse of an extraordinary effort Friday to reach a deal covering all the cases. Polster had summoned the chief executives of the distributors and representatives of the other two companies to his courtroom.

Also called were the plaintiffs’ lawyers and the four attorneys general who represented dozens of states that have been negotiating separately with the drug companies.

Polster shuttled among the parties, trying to find common ground. But after about 10 hours of talks, the parties were still far apart.

Negotiations continued over the weekend between the two Ohio counties and the drug companies, Hanly said. As of late Saturday, the distributors were offering $90 million, and the counties were holding out for $250 million. For the plaintiffs, he said, $200 million was an important target. Eventually, he said, the distributors raised their offer to $215 million, and the plaintiffs accepted.

They claim in this article that FOUR DRUG COMPANIES made a settlement… of the four companies that made the settlement, THREE WERE WHOLESALER and one was a generic pharma manufacturer. None of the companies in this settlement has direct access to pt information. Generally speaking a generic manufacturer does not even have a detail/marketing staff seeing doctors and neither does drug wholesalers.

A entity that seems to get a PASS in all of this is the DEA … they are the ones who maintain the ARCOS database https://www.deadiversion.usdoj.gov/arcos/index.html .. so for all of these years that these four entities were supposedly selling all of these opiate doses… the DEA was not looking at the database that they were maintaining on these very same medications ?  OR.. they were looking and chose to turn a blind eye to what was going on ?

Does it seem strange that the DEA is part of our judicial system and these dollar settlements are going to other parts of the judicial system – all the law firms that have taken these cases on a contingencies basis – they get a PER-CENT of the proceeds and the rest of the $$$ goes to cities/counties/states and it has been reported that many/some of these agreements are written that those bureaucracies getting these $$$ may or may not have to put it to the use that they were claiming that the bureaucracies were harmed by the actions of these defendants.

This is the same thing that happened with the monies from the billions being distributed from the large tobacco settlement – that was to be paid out annually – from about 20 yrs ago and that money will dry up in a few years…  It would appear that this opiate crisis is the bureaucracies new “golden goose”

Gee, Pain Pills Are Not Killers. And the Sun Rises in the East. Who Knew?

Gee, Pain Pills Are Not Killers. And the Sun Rises in the East. Who Knew?

https://www.acsh.org/news/2019/10/21/gee-pain-pills-are-not-killers-and-sun-rises-east-who-knew-14349

In 2016 I testified at an FDA hearing about the “opioid crisis,” which was starting to make its way into the news in a big way. I was the last of 15 speakers, which included, among others, addiction specialists, physicians, patient advocates and parents whose children had died from drug overdoses. 

The word “fentanyl” was not mentioned even once until I spoke, when I predicted that it, which I referred to as the “devil in the room,” was the real threat. Some people looked at me as if I had sprouted moose antlers. I could almost hear them thinking “what is this guy talking about?” Despite the fact that fentanyl had just begun to pour into the US two years earlier the hundreds of people in the room seemed to be oblivious to what was really going on.

J. Bloom, Presentation to the FDA Science Board, White Oak MD, March 4th, 2016. In 2010 Purdue Pharma launched a new formulation OxyContin that was difficult to abuse. Heroin use (and death rates) took off immediately as addicts switched to street heroin, which is far more dangerous than any pill, this the surge in deaths. Fentanyl, which is more powerful, cheaper, and easier to transport, began to replace heroin soon after it entered the US three years later. 

Despite rhetoric from the oblivious media and opportunistic politicians, and distorted propaganda from shady groups like Physicians for Responsible Opioid Prescribing, what was really going on was perfectly obvious. I spent the next 3+ years banging my head against the periodic table on the wall, trying to bring home the message that we were fighting the wrong battle; injectables, not pills, were the primary cause of the soaring rate of lethal opioid overdoses and the more that the pills were restricted the more deaths would occur.
 

Yet, it wasn’t until 2018 when a study confirmed what was already obvious five years earlier (See ‘Study Links Rising Heroin Deaths To 2010 OxyContin Reformulation.Duh.’). The crackdown on prescribing (1) opioid analgesics was not only associated with a spike in overdose deaths, but it also caused it. 

A recent report in Public Health Reports further drives home the point that I made in 2016. “The Contribution of Prescribed and Illicit Opioids to Fatal Overdoses in Massachusetts, 2013-2015” clearly identifies fentanyl as the drug responsible for tens of thousands of people dying each year. It clarifies something that should have needed no clarifying in the first place (Figure 1). 

Figure 1. (Top) Overdose deaths from all opioids rose by about 30,000 between 2013-2017, virtually all of the increase (Bottom) due to fentanyl (yellow line) and heroin (green line). Deaths from prescription analgesics (blue line) remained stable during this same time. Source: National Institute on Drug Abuse

Anyone who has been following the real story (2) shouldn’t be the least bit surprised surprised about any of the following:

Of the 2916 people who died in Massachusetts between 2013-2015 (and had complete toxicology reports): 

  • 1789 (61%) had heroin detected.
  • 1322 (45%) had fentanyl detected.
  • Of the 491 (17%) people who died (and had an active prescription for an opioid on the day that they died), the prescription drugs were detected only 1.3% of the time.
  • In other words, almost without exception, legally prescribed pills did not kill the patients that they were intended to treat. So much for the injury-pain-addiction-overdose theory. It was stupid in the first place.

If this isn’t convincing enough, try Figure 2.

Figure 2. The bottom graph from Figure 1, when blown up, reveals that the article in Public Health Reports is examining the tip of an iceberg. Although fentanyl was already one of the two “killer opioids” between 2013-15 its impact was only beginning to be felt. During 2015-17 – the two years after the report – fentanyl deaths skyrocketed.

So, it would not be unreasonable for one to conclude that after 2017 fentanyl (3) was responsible for almost all opioid deaths in Massachusetts and prescription narcotics virtually none. One would be correct (Figure 3).

Figure 3. In mid-2014 (Massachusetts) prescription opioids (turquoise arrow) were present in more than 35% of tox samples. By 1Q 2019 that number had dropped to about 10%. Conversely, fentanyl was present in about 25% of samples in mid-2014 but by 1Q 2019 it was present in nearly all samples. Source: Massachusetts Department of Health.

TAKE HOME MESSAGES:

  • Fentanyl gained a foothold in the US beginning in 2013 because there was a booming heroin market.
  • Overdose deaths from all opioids rose steadily in Massachusetts between 2013-15, with fentanyl being a major factor.
  • Even during this time, when fentanyl use was just beginning to take root in the US, legally prescribed prescription opioid narcotics were responsible for only a minor percentage of total opioid deaths.
  • In Massachusetts between 2013-15 fentanyl was detected in about half of the people who died.
  • By 1Q 2019 that number was >90%.
  • It is virtually certain that when the 2013-15 numbers are updated to include 2017-19, the deaths from legally prescribed narcotics will be negligible.
  • It is also a virtual certainty that almost all deaths will be due to fentanyl.
  • By all means, let’s keep suing opioid makers, restricting their manufacture and prescription. But don’t expect this to change. Except maybe for the worse:

Source: (Top) Pain News Network/DA. (Bottom) National Institute on Drug Abuse

Keep your eyes on the orange box. Do you see any relationship between fewer prescriptions and more deaths?

Just asking. 

NOTES:

(1) The crackdown is spreading. Now the DEA wants to dictate how much of which drug can be manufactured. Does this sound like a good idea? Didn’t think so.

(2) My articles during this time have been compiled and categorized (See Analyzing The Opioid Crisis: 65 Articles By Dr. Josh Bloom).

(3) When I write “fentanyl” it does not mean pharmaceutical fentanyl, which is sold for severe pain in patches, candy, nasal sprays… in very small doses, typically a fraction of a milligram. I mean pounds/tons of illicit fentanyl and its analogs manufactured (mostly) in China. Pharmaceutical fentanyl is not a significant contributor to the carnage that is going on.

DEA on adjusting quotas for opioids

DEA on adjusting quotas for opioids

In our series, Issues that Matter, we are focusing on the opioid crisis. According to the CDC, almost 400,000 Americans died from prescription and illicit opioid overdoses between 1999 and 2017. In 2017, more than 2.1 million Americans were addicted to opioids. This Saturday, the Drug Enforcement Administration is hosting National Prescription Drug Take Back Day, where you can turn in your unused and unwanted medications, no questions asked. Acting DEA Administrator Uttam Dhillon joins “CBS This Morning” to discuss the initiative.

These people are so CLUELESS and what is bad is that apparently they don’t have a clue that they are CLUELESS… they are stating that it is “harmful for the environment” to flush unused meds down the toilet…

When a person takes a dose of a medication… it doesn’t magically “disappears” … it is metabolized in the body and some metabolites from the medication is excreted in the pt’s urine or feces… and guess where those go… 

People dumping excessive medication that is not taken … will not begin to move the needle on the parts per million or billion that is able to be measured in the water table or ground.

I wonder how the DEA determines the “correct amount” of opiates for all the 100 million chronic pain pts ?

 

SUICIDE: who you gonna call ?

Until a few years ago … suicide was considered a CRIME… now we have some 6 states that have laws that makes “death with dignity” condones certain suicides within the guidelines that the state consider acceptable and reportedly a large number of states are considering passing same/similar laws.

It is still ILLEGAL to assist and/or encourage suicide.. in fact a young woman https://www.womenshealthmag.com/life/a28326092/michelle-carter-sentence-texting-suicide-case/

got a 30 month sentence for INVOLUNTARY MANSLAUGHTER for encouraging her boyfriend to commit suicide – mostly via text messages.

prescribers, pharmacists, nurses are considered “learned professionals” and should be full aware of the consequences of denying, withholding or reducing a pt’s medication for chronic conditions – especially subjective diseases such as chronic pain, anxiety, depression or other mental health issues.

Could it be that all opiate OD deaths have been classified as “accidental overdose” because would our judicial system would have to investigate a suicide and spend money on the investigation and maybe be forced to charge someone with assisting the suicide ?  But it also serves the DEA’s agenda that we have a opiate crisis that is being fueled by Rx opiates.

We know that there are abt ONE MILLION attempted suicide EVERY YEAR and that abt 50,000/yr deaths from suicide.. what we don’t know is how many of those deaths or attempts are because chronic pain pts or other pts dealing with subjective diseases are being denied their medically necessary medication.  We also don’t know how many of those deaths are because those serious/dedicated substance abusers are just “sick & tired” of dealing with being “dope sick” and suffering thru going thru withdrawal and just has decided to “end it all”… and their death is not really a accident.

We have also heard of chronic pain pts leaving suicide notes that seem to “disappear” after the fact… Who would make a suicide note disappear… the relatives because they are ashamed that their relative committed suicide, because suicide would cause any/all life insurance policies to become null/void or back to the agenda of the DEA and every “body” they can count… helps their agenda of the opiate crisis.

What would happen if the person who has committed suicide, has sent out a “suicide video” or sent a registered letter to the local prosecuting attorney accusing their prescriber, pharmacist, insurance/PBM company or the company that any of these healthcare professionals work for that have established policies that caused the pt to be denied their necessary medication.

Why is it that we seldom – if ever – hear from a family member of a chronic pain pt who has committed suicide .. like we hear from family members of those who OD from a claimed opiate OD… saying… “we never want another family to go thru what we did… losing a family member to a opiate OD…”  More likely one will hear from a chronic pain pt’s family after a suicide …” he/she is now at peace and out of pain “… and they get back to living their lives…

BUT… how does someone who is planning on a suicide and sends a certified “suicide letter” to the local prosecutor… who is going to get the return post card that it was signed for ? Would a prosecutor even consider taking action against the professionals or corporation that contributed to the suicide ? Could any of those entities be accused or charged with assisting suicide, involuntary manslaughter or some other law that they could legally charged with breaking and contributing to a person’s death ?

I doubt if FB, twitter,  youtube or any other media outlet would allow a “suicide video” to be published or if published it would probably be quickly taken down.

Could/should the pt entrust a copy of the letter or video with another chronic pain pt friend… to send it to the media.. if the local prosecutor fails to take action ?

Probably the only place that such a letter or video could be published without immediate repercussion is with a chronic pain advocate that has their own website domain and no one that would have any authority to force it to be taken down.

 

 

 

How the DEA is cracking down on resurgence of meth

How the DEA is cracking down on resurgence of meth

https://www.10tv.com/article/how-dea-cracking-down-resurgence-meth-2019-oct

Opioids aren’t the only drugs causing major problems in our area. ​Methamphetamines are making a big come-back.

The number of arrests for methamphetamines has grown 5 times in the Southern District of Ohio just since 2014.

“There is no shortage of work,” said Mauricio Jimenez, Assistant Special Agent in Charge for the Drug Enforcement Administration.

Advertisement – Story continues below

On Sunday, there were 5 opioid overdose deaths in Franklin County.

“This area was once hit hard with fentanyl and opioids, and now it’s starting to move towards meth. There’s a certain element of violence,” Jimenez explained.

Opioids aren’t Mauricio Jimenez’s biggest concern.

“We’ve seen a switch from people who were addicted to heroin or fentanyl to methamphetamine because meth they know won’t kill them like fentanyl would,” Jimenez said.

Jimenez explained methamphetamines are now rampant in southern and central Ohio.

“Now we are seeing street-level distributors with ounces of meth in their pockets because it is readily available and cheap,” Jimenez said.

DEA arrests for methamphetamines in our area have jumped from 17 in 2015 to 86 in 2019.

“The quality of meth today is completely different than what we saw 20 years ago. It’s about as pure as pure gets,” Jimenez explained.

Jimenez says most of it is coming from the southwest and Mexico. He adds, the DEA is teaming up with local departments to nab as much of the drugs as they can before it hits the streets in our area.

“I don’t think we are ever going to see the days where this is completely done,” Jimenez said.

 

CVS: many mistakes actually do happen and are covered up

Thought I would share the story in case you would like to post it anonymously. A pharmacist in Hebron Ct was supposed to dispense a prescription for liquid propranolol. The mom who is a family friend called me hysterical because the medication looked different. I told her to promptly return to CVS and demand to see the stock bottle and its contents color. It turns out it was the wrong medication she does not know the name of med that was given to her 3 year old daughter, but she was angry & frightened & burst into tears after realizing how serious a situation this was. She asked me what do people do if they don’t know if pharmacist personally to ask these questions. She is supposed to get a call from the DM. I told her to emphasize that Cvs needs to increase staffing levels pronto! I also told her to go public with this but she is afraid to do so as she is a business owner in town. When I told her how many mistakes actually do happen and are covered up she changed her mind and said after speaking to the DM she will decide whether not to go public with her issue!

How Dr. Drew Sold His Cred to Big Pharma

Who thought he was off the air called #CPPS #IPPS,
“BORDERLINE DRUGGIES”
How Dr. Drew Sold His Cred to Big Pharma
The health journalist for HLN comes under scrutiny after admitting he helped a major drug company promote antidepressants to consumers.

Drew Pinsky, with fellow CNN host Piers Morgan, during the Turner Broadcasting Television Critics Association winter press tour in Pasadena, California (Mario Anzuoni/Reuters)

On Monday night, Dr. Drew Pinsky’s program on HLN — the network formerly known as CNN Headline News — explored the everyman’s dilemma of “how to tell if your doctor is hooked on drugs.” Informative as the segment proved to be, one surefire signal your doc’s hooked didn’t come up. Any time federal prosecutors release a cache of documents proving that a pharmaceutical company paid your doctor $275,000 as part of a criminal plan to market its antidepressant for unapproved uses, your doctor has a drug problem. Dr. Pinsky is one of many physicians GlaxoSmithKline (formerly Glaxo Wellcome) sent around to trump up Wellbutrin’s potential uses outside of FDA ground rules. His activities, elaborately decorated as a public educational campaign, amounted to a convenient contraption GSK used to launder illegal marketing messages.

“Dr. Drew” is a board-certified addiction specialist who rose to national prominence through his long-running radio show, Loveline, which delivers sexual health and relationship advice to its confused, vulnerable, and curious callers. MTV picked up the show, catapulting the telegenic Dr. Drew into true media stardom. He’s built a wide-ranging career including shows like “Celebrity Rehab with Dr. Drew,” and since last year he’s hosted a nightly program for HLN. Dr. Drew’s minor empire is built on audiences who’ve grown to trust his medical opinion.

Though GSK pled criminally guilty and will fork out $3 billion in penalties for violations ranging from illegal marketing to misreporting drug prices, Pinsky’s role as GSK’s enabler doesn’t constitute a crime. But the extent to which he deceived his audiences as part of the GSK-prescribed program, which involved town halls, writings, and media appearances, ought to end his career with CNN. Aware that Wellbutrin’s main competition, the class of drugs known as SSRIs, came with the unfortunate risk of lowering libido, GSK’s sales department developed an ingenious plan to use Dr. Pinsky as the face of a public education campaign getting the word out about these side effects and “other effective antidepressants that do not disrupt sexual desire and function,” as GSK’s website said. Other antidepressants then available that didn’t seem to depress sex drive included Serzone, which is now off the market, and Remeron. But both had other complicating factors that made Wellbutrin the better choice in such situations.

Dr. Drew hasn’t apologized and has instead issued a statement saying his comments about Wellbutrin were based on his own clinical experience. That’s the claim most doctors make when pressed about giving remarkably on-message pharma-sponsored talks. Whether or not you buy his claim that GSK’s money made no difference to him, Dr. Drew’s role was suspect in speaking to an audience that was both unwitting of his paid status and medically unsophisticated. Similar to the audience tuning in to him on HLN every night, he was speaking to people who were relying on his medical authority. Clinical audiences have a base of knowledge they can use to evaluate claims that Dr. Drew aired, such as his assertion on one radio program that Wellbutrin can make women multiorgasmic. The general public does not.

The other CNN host facing charges of public trust violation, Piers Morgan, has so far survived calls for his resignation over his alleged but unproven link to Britain’s phone hacking scandal. Now CNN, mired in its lowest ratings in decades, faces a similar decision accompanied by fewer options. When I brought up the Piers Morgan affair in an interview, Turner Broadcasting spokesperson Carolyn Disbrow tried to distance HLN from CNN at large. “You know we’re separate, right?,” she said.

According to documents available on the Justice Department’s website, Dr. Drew broadcast GSK’s intended message while keeping audiences in the dark about being a paid spokesman. Pinsky has also admitted as much in a statement. Although Turner told me that Dr. Drew’s GSK payments “occurred well before the time he became affiliated with [HLN],” Dr. Drew’s habit of taking money from pharma doesn’t appear to end there. ProPublica’s “Dollars for Docs” database reports that Johnson & Johnson paid Dr. Drew $74,500 just two years ago. Was that more undercover messaging? Dr. Drew’s brief statement doesn’t address J&J or the most important questions: what else are we missing, and what’s going on now?

While pondering Dr. Drew’s next move in this scandal, I reached out to Dr. Daniel Carlat, a psychiatrist who once made big bucks giving talks for Wyeth about its antidepressant Effexor. Dr. Carlat went on to redeem himself by founding a pharma-free continuing medical education company, writing about his experience, and is now serving as director of the Pew Prescription Project, which aims at getting the Physician Payments Sunshine law implemented as quickly as possible. Calling Dr. Drew’s actions improper, Carlat says “doctors would think twice about accepting such payments if a strong disclosure law were in effect.” Recently, the Center for Medicare and Medicaid Services delayed its estimated Sunshine implementation date until January 2013. Though all physicians must make plans for 2013, back in 1999 Dr. Drew could never have predicted the confluence of events that brought his $275,000 deal into public view today.

Dr. Drew happens to sell ad spots on his Twitter account. He dutifully identifies his sponsored messages on Twitter, unlike the messages he delivered for GSK. He tries not to overdo it. “It’s treacherous. I don’t want people to think I’m exploiting my followers,” Dr. Drew once told a CNN reporter. That’s exactly what I’m thinking.

We want to hear what you think about this article. Submit a letter to the editor or write to letters@theatlantic.com.

FORD VOX, MD, is a physician, based in Atlanta, who specializes in caring for people with complex brain injuries. He has written for Newsweek, Slate, and the Los Angeles Times.

How Dr. Drew Sold His Cred to Big Pharma

https://www.theatlantic.com/health/archive/2012/07/how-dr-drew-sold-his-cred-to-big-pharma/259473/

The health journalist for HLN comes under scrutiny after admitting he helped a major drug company promote antidepressants to consumers.

Drew Pinsky, with fellow CNN host Piers Morgan, during the Turner Broadcasting Television Critics Association winter press tour in Pasadena, California (Mario Anzuoni/Reuters)

On Monday night, Dr. Drew Pinsky’s program on HLN — the network formerly known as CNN Headline News — explored the everyman’s dilemma of “how to tell if your doctor is hooked on drugs.” Informative as the segment proved to be, one surefire signal your doc’s hooked didn’t come up. Any time federal prosecutors release a cache of documents proving that a pharmaceutical company paid your doctor $275,000 as part of a criminal plan to market its antidepressant for unapproved uses, your doctor has a drug problem. Dr. Pinsky is one of many physicians GlaxoSmithKline (formerly Glaxo Wellcome) sent around to trump up Wellbutrin’s potential uses outside of FDA ground rules. His activities, elaborately decorated as a public educational campaign, amounted to a convenient contraption GSK used to launder illegal marketing messages.
“Dr. Drew” is a board-certified addiction specialist who rose to national prominence through his long-running radio show, Loveline, which delivers sexual health and relationship advice to its confused, vulnerable, and curious callers. MTV picked up the show, catapulting the telegenic Dr. Drew into true media stardom. He’s built a wide-ranging career including shows like “Celebrity Rehab with Dr. Drew,” and since last year he’s hosted a nightly program for HLN. Dr. Drew’s minor empire is built on audiences who’ve grown to trust his medical opinion.
Though GSK pled criminally guilty and will fork out $3 billion in penalties for violations ranging from illegal marketing to misreporting drug prices, Pinsky’s role as GSK’s enabler doesn’t constitute a crime. But the extent to which he deceived his audiences as part of the GSK-prescribed program, which involved town halls, writings, and media appearances, ought to end his career with CNN. Aware that Wellbutrin’s main competition, the class of drugs known as SSRIs, came with the unfortunate risk of lowering libido, GSK’s sales department developed an ingenious plan to use Dr. Pinsky as the face of a public education campaign getting the word out about these side effects and “other effective antidepressants that do not disrupt sexual desire and function,” as GSK’s website said. Other antidepressants then available that didn’t seem to depress sex drive included Serzone, which is now off the market, and Remeron. But both had other complicating factors that made Wellbutrin the better choice in such situations.
Dr. Drew hasn’t apologized and has instead issued a statement saying his comments about Wellbutrin were based on his own clinical experience. That’s the claim most doctors make when pressed about giving remarkably on-message pharma-sponsored talks. Whether or not you buy his claim that GSK’s money made no difference to him, Dr. Drew’s role was suspect in speaking to an audience that was both unwitting of his paid status and medically unsophisticated. Similar to the audience tuning in to him on HLN every night, he was speaking to people who were relying on his medical authority. Clinical audiences have a base of knowledge they can use to evaluate claims that Dr. Drew aired, such as his assertion on one radio program that Wellbutrin can make women multiorgasmic. The general public does not.
The other CNN host facing charges of public trust violation, Piers Morgan, has so far survived calls for his resignation over his alleged but unproven link to Britain’s phone hacking scandal. Now CNN, mired in its lowest ratings in decades, faces a similar decision accompanied by fewer options. When I brought up the Piers Morgan affair in an interview, Turner Broadcasting spokesperson Carolyn Disbrow tried to distance HLN from CNN at large. “You know we’re separate, right?,” she said. 
According to documents available on the Justice Department’s website, Dr. Drew broadcast GSK’s intended message while keeping audiences in the dark about being a paid spokesman. Pinsky has also admitted as much in a statement. Although Turner told me that Dr. Drew’s GSK payments “occurred well before the time he became affiliated with [HLN],” Dr. Drew’s habit of taking money from pharma doesn’t appear to end there. ProPublica’s “Dollars for Docs” database reports that Johnson & Johnson paid Dr. Drew $74,500 just two years ago. Was that more undercover messaging? Dr. Drew’s brief statement doesn’t address J&J or the most important questions: what else are we missing, and what’s going on now?
While pondering Dr. Drew’s next move in this scandal, I reached out to Dr. Daniel Carlat, a psychiatrist who once made big bucks giving talks for Wyeth about its antidepressant Effexor. Dr. Carlat went on to redeem himself by founding a pharma-free continuing medical education company, writing about his experience, and is now serving as director of the Pew Prescription Project, which aims at getting the Physician Payments Sunshine law implemented as quickly as possible. Calling Dr. Drew’s actions improper, Carlat says “doctors would think twice about accepting such payments if a strong disclosure law were in effect.” Recently, the Center for Medicare and Medicaid Services delayed its estimated Sunshine implementation date until January 2013. Though all physicians must make plans for 2013, back in 1999 Dr. Drew could never have predicted the confluence of events that brought his $275,000 deal into public view today.
Dr. Drew happens to sell ad spots on his Twitter account. He dutifully identifies his sponsored messages on Twitter, unlike the messages he delivered for GSK. He tries not to overdo it. “It’s treacherous. I don’t want people to think I’m exploiting my followers,” Dr. Drew once told a CNN reporter. That’s exactly what I’m thinking.

U.S. Attorney for Oregon Indicts Three Chinese Nationals for Laundering Drug Money: All three defendants are at-large and believed to be outside the U.S

U.S. Attorney for Oregon Indicts Three Chinese Nationals for Laundering Drug Money

https://canbynowpod.com/crime/u-s-attorney-for-oregon-indicts-three-chinese-nationals-for-laundering-drug-money/

Three Chinese nationals were indicted by the U.S. attorney’s office in Oregon this week for their roles in a complex scheme to launder proceeds from the sale of illegal narcotics by facilitating the transfer of bulk cash from Mexican drug trafficking organizations.

Shefeng Su, Xinhua Li Yan and Xiancong Su, are each charged with conspiracy to commit money laundering. Shefeng Su and Li Yan were residents of Portland during the time frame alleged in the indictment.

According to the indictment, the defendants’ money laundering scheme was designed to remedy two separate problems: drug trafficking organizations’ inability to repatriate drug proceeds into the Mexican banking system and the restrictions by China’s capital flight laws from transferring large sums of money held in Chinese bank accounts for use abroad.

Drug traffickers are challenged by their inability to transport U.S. currency acquired from the sale of illegal narcotics to Mexico while avoiding detection by law enforcement and Mexican banking regulators. White Sands are getting involved to keep the drugs at bay as it was damaging the youth. Mexico’s anti-money laundering regulations limit the amount of cash deposits of U.S. dollars that Mexican financial institutions can receive.

As a result, drug trafficking organizations work with professional money launderers to bundle and sell bulk U.S. dollars in order to convert them to pesos, a more readily depositable currency in Mexico.

Meanwhile, Chinese nationals living outside China are challenged by China’s limit on the amount of personal funds that can be transferred out of Chinese bank accounts for use in a foreign country. Currently, China limits these transfers to $50,000 per year. As a result, some Chinese nationals have a need to acquire large quantities of U.S. dollars via other means.

The defendants’ scheme facilitated the transfer of cash between these two groups. Their money laundering organization would facilitate the transfer of funds from the buyer’s Chinese bank account to another Chinese bank account held by the money laundering organization.

Once the Chinese renminbi (RMB) were transferred between these bank accounts, the funds were repatriated back to Mexico and converted to pesos to complete the money laundering cycle. This scheme has been described by some as the “Chinese Underground Banking System.”

All three defendants are at-large and believed to be outside the U.S. This case was investigated by the Drug Enforcement Administration (DEA) and is being prosecuted by the U.S. Attorney’s Office for the District of Oregon.

An indictment is only an accusation of a crime, and defendants are presumed innocent unless and until proven guilty.

The DEA/judicial system will always try to go after the money… even if they are only getting about 10% of all the illegal substances are getting seized and destroyed…   Nothing like indicting people who are not in the country and unlikely the people will ever get served, jailed and go to trial.  I guess that it is important for those within our judicial system to do something to demonstrate that they are focused on the job at hand.. No matter how futile their actions are.

If you don’t compare your med costs under Part D – YOU MAY BE VERY SORRY !

This is the first year that I have compared Part D programs for us.  Below is the “short version” of that comparison. Barb has had a part D prgm policy since its inception in 2006 with Silver Script (a CVS Health company) . She went on Medicare disability in 1996 and between 1996 and 2006 all of her medications were paid for “OUT OF POCKET”  It was not unusual during that time frame that for a 90 days supply of all of her medication would cost between $2000- $3000.  One of Barb’s medications required a PRIOR AUTHORIZATION and copay was $600 and change for a 90 day supply.  It wasn’t until last year that one of Pharmacists at the Winn-DIxie that we use while in Florida suggested that I use the “house drug card” that Winn Dixie uses that would bring the cost down to $190 and change for a 90 days supply… CASH AND NO PA… 🙂

Upon returning to our Indiana home, I discovered that at one of the BIG BOX STORES… I could purchase – FOR CASH – the same 90 days supply for < $90.

For 2020 Silver Scripts using the  https://www.medicare.gov/plan-compare/#/?lang=en to compare out of pocket costs of the various Part D prgms… if you are currently on a Part D prgm, all you have to do is create or login to Medicare and they will pull up all your meds to help you compare the costs of the various prgms available in your zip code.

Silver scripts has a stated cost of this particular med of $3520.09 for a 90 days supply and the new policy we are probably going to sign up for lists the cost as $97.42 after the deductible has been met.  With CVS health being the largest pharmacy chain in the country… and Silver Script being one of the TOP THREE PART D PRGMS …one would think that they would be able to purchase this med at or near the same cost as other pharmacies or PBM’s.

They also – sort of – play a trick with the $$ numbers… unless the pt is paying attention… they may not notice that the pt’s cost is the same before the deductible as it is after the deductible has been met… which means … IT IS NOT A COVERED MEDICATION…  pt MAY BE ABLE TO GET IT COVERED VIA A PRIOR AUTHORIZATION…. but still have to PAY HUNDREDS more than the medication can be purchased for CASH at many pharmacies.

Me on the other hand…  I take SIX GENERIC RXS and estimated annual cost via Silver Scripts is $1596.88 and thru the plan we are probably going to sign up for would be $294.24… I would not even meet the $450 annual deductible !!!

Caremark – the PBM that CVS Health owns – has been caught overcharging the Arkansas state employee prescription prgm https://www.kark.com/news/lawmakers-pharmacists-meet-with-cvs-over-regulation-of-pharmacy-benefit-managers/ as well as the Ohio’s state Medicaid HMO prgm. https://insurancenewsnet.com/oarticle/pharmacy-middlemen-reap-millions-from-medicaid